Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: The influence of dose and dose per fraction

Future Oncology

Volumn 3, Issue 6, 2007, Pages 649-654

  Lee, W Robert ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dose escalation; Hypofractionation; Image guided radiation therapy; Intensity modulated radiation therapy; Prostate cancer; Radiotherapy; Randomized trials

Indexed keywords

GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

BIOCHEMISTRY; BLADDER DISEASE; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEXUAL DYSFUNCTION; TECHNOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

BRACHYTHERAPY; CLINICAL TRIALS AS TOPIC; DOSE FRACTIONATION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIATION TOLERANCE;

EID: 38049103158     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.6.649     Document Type: Review

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Thompson I, Thrasher JB, Aus G et al.: Guideline fbr the management of clinically localized prostate cancer: 2007 update J. Urol. 177(6), 2106-2131 (2007).
3. Penson DF, Feng Z, Kuniyuld A et al.: General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J. Clin. Oncol. 21(6), 1147-1154 (2003).
4. Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A: Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur. J. Cancer 41(6), 908-921 (2005).
5. Galvin JM, De Neve W: Intensity modulating and other radiation therapy devices for dose painting. J. Clin. Oncol. 25(8), 924-930 (2007).
6. Kupelian P, Meyer JL: Prostate cancer: image guidance and adaptive therapy. Front Radiat Ther. Oncol. 40, 289-314 (2007).
7. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 37(5), 1035-1041 (1997).
8. Roach M III, Hanks G, Thames H Jr et al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65(4), 965-974 (2006).
9. Hanks GE, Lee WR, Hanlon AL et al.: Conformal technique dose escalation fbr prostate cancer: biochemical evidence of improved rancer control with higher doses in patients with pretreatment proscate-specific antigen or = 10 NG/ML. Int. J. Radiat. Oncol. Biol Phys. 35(5), 861-868 (1996).
10. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA: Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int. J Radiat. Oncol. Biol. Phys. 46(3), 567-574 (2000).
11. Pollack A, Zagars GK: External beam radiotherapy dose response of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 39(5), 1011-1018 (1997).
12. Zelefsky MJ, Leibel SA, Gaudin PB et al.: Dose escalation with three-dimensional conformal radiation therapy affects die outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 41(3), 491-500 (1998).
13. Pollack A, Zagars GK. Starkschall G et al.: Prostate cancer radiation dose response: results of the M. D. Anderson Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53(5), 1097-1105 (2002).
14. Kuban D, Tucker S, Dong L et al.: Long-term results of a randomized dose escalation trial for prostate cancer. Abstract Int. J. Radiat. Oncol. Biol. Phys. 66(3), S8-S9 (2006) (15).
15. Zietman AL, Desilvio ML, Slater JD et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10), 1233-1239 (2005).
16. Peeters ST, Heemsbergen WD, Koper PC et al.: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24(13), 1990-1996 (2006).
17. Dearnaley DP, Sydes MR, Graham JD et al.: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randornised controlled trial. Lancet Oncol. 8(6), 475-487 (2007).
18. Fowler JF, Ritter MA, Chappell RJ, Branner DJ: What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56(4), 1093-1104 (2003).
19. Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 44(3), 265-276 (2005).
20. Kupelian PA, Reddy CA, Klein EA, Willoughby TR: Shore-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int. J. Radiat. Oncol. Biol. Phys. 51(4), 988-993 (2001).
21. Kupelian PA,Willoughby TR, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 gy per fraction) for localized prostate cancer: cleveland clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 68(5), 1424-1430 (2007).
22. Martin JM, Rosewall T, Bayley A et al.: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 30 June 2007 (Epub ahead of print).
23. Madsen BL, Hsi RA, Pham. HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int. J. Radiat. Oncol. Biol Phys. 67(4), 1099-1105 (2007).
24. Pollack A, Hanlon AL, Horwitz FM et al.: Dosimetry and preliminary acute toxicity in die first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 64(2), 518-526 (2006).
25. Dearnaley DP, Syndikus I, Norman AR et al.: Conventional or hypofractionated high dose intensity modulated radiotherapy in prostate cancer: preliminary report on acute and late toxicity. The Prostate Cancer Symposium: A Multidisciplinary Approach (2007) (Absuac 303).
26. Litzenberg DW, Willoughby TR, Balter JM et al.: Positional stability of electromagnetic transponders used for prostate localization and continuous, real-time tracking Int. J. Radiat Oncol. Biol. Phys. 68 (4), 1199-1206 (2007).